Tyler Aaron Smith

Dr. Tyler Aaron Smith

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
CGCameron L. Ghergherehchi
Cameron L. Ghergherehchi
MMMichelle Mikesh
Michelle Mikesh
DSDale R. Sengelaub
Dale R. Sengelaub
DJDavid M. Jackson
David M. Jackson
TSTyler Aaron Smith
Tyler Aaron Smith
GBGeorge D Bittner
George D Bittner

5 January 2016 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
CGCameron L. Ghergherehchi
Cameron L. Ghergherehchi
GBGeorge D Bittner
George D Bittner
RHRobert Louis Hastings
Robert Louis Hastings
MMMichelle Mikesh
Michelle Mikesh
DRD. Colton Riley
D. Colton Riley
PDPatrick J. Dunne
Patrick J. Dunne

15 September 2020 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
TSTyler Aaron Smith
Tyler Aaron Smith
CGCameron L. Ghergherehchi
Cameron L. Ghergherehchi
MMMichelle Mikesh
Michelle Mikesh
JSJaimie T. Shores
Jaimie T. Shores
HTHaley O. Tucker
Haley O. Tucker
GBGeorge D Bittner
George D Bittner

1 March 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
JGJenna L Gordon
Jenna L Gordon
KHKristin J. Hinsen
Kristin J. Hinsen
MRMelissa Reynolds
Melissa Reynolds
TSTyler Aaron Smith
Tyler Aaron Smith
HTHaley Tucker
Haley Tucker
Mark A. BrownMark A. Brown
Mark A. Brown
The most common extracranial solid tumor in childhood, paediatric neuroblastoma, is frequently diagnosed at advanced stages and identified as high risk. High risk neuroblastoma is aggressive and unpredictable, resulting in poor prognosis and only ∼40% five-year survival rates. Herein, nitric oxide (NO) delivered via the S-nitrosothiol, S-nitrosoglutathione (GSNO), is explored as an anticancer therapeutic in various neuroblastoma lines. After 24 h of treatment with GSNO, cell viability assays, as assessed by resazurin and MTT ((3-4,5-dimethylthiazol-2-yl)-2,5-diphyltetrazolium bromide), consistently identified a moderate, ∼13–29%, decrease in metabolic activity, colony formation assays revealed notably significant reduction of clonogenic activity, and cytotoxicity assays revealed a visibly significant reduction of total number of cells and live cells as well as an increase in number of dead cells in treated cells versus untreated cells. Thrillingly, RNA-sequence analysis provided highly valuable information regarding the differentially expressed genes in treated samples versus control samples as well as insight into the mechanism of action of NO as an anticancer therapeutic. Favorably, the collective results from these analyses exhibited tumoricidal, non-tumour promoting, and discriminatory characteristics, illuminating the feasibility and significance of NO as a cytotoxic adjuvant in neuroblastoma treatment.

2 October 2020 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
TSTyler Aaron Smith
Tyler Aaron Smith
CGCameron L. Ghergherehchi
Cameron L. Ghergherehchi
HTHaley O. Tucker
Haley O. Tucker
GBGeorge D Bittner
George D Bittner
Background: Current methods to repair ablation-type peripheral nerve injuries (PNIs) using peripheral nerve allografts (PNAs) often result in poor functional recovery due to immunological rejection as well as to slow and inaccurate outgrowth of regenerating axonal sprouts. In contrast, ablation-type PNIs repaired by PNAs, using a multistep protocol in which one step employs the membrane fusogen polyethylene glycol (PEG), permanently restore sciatic-mediated behaviors within weeks. Axons and cells within PEG-fused PNAs remain viable, even though outbred host and donor tissues are neither immunosuppressed nor tissue matched. PEG-fused PNAs exhibit significantly reduced T cell and macrophage infiltration, expression of major histocompatibility complex I/II and consistently low apoptosis. In this study, we analyzed the coding transcriptome of PEG-fused PNAs to examine possible mechanisms underlying immunosuppression.Methods: Ablation-type sciatic PNIs in adult Sprague-Dawley rats were repaired using PNAs and a PEG-fusion protocol combined with neurorrhaphy. Electrophysiological and behavioral tests confirmed successful PEG-fusion of PNAs. RNA sequencing analyzed differential expression profiles of protein-coding genes between PEG-fused PNAs and negative control PNAs (not treated with PEG) at 14 days PO, along with unoperated control nerves. Sequencing results were validated by quantitative reverse transcription PCR (RT-qPCR), and in some cases, immunohistochemistry.Results: PEG-fused PNAs display significant downregulation of many gene transcripts associated with innate and adaptive allorejection responses. Schwann cell-associated transcripts are often upregulated, and cellular processes such as extracellular matrix remodeling and cell/tissue development are particularly enriched. Transcripts encoding several potentially immunosuppressive proteins (e.g., thrombospondins 1 and 2) also are upregulated in PEG-fused PNAs.Conclusions: This study is the first to characterize the coding transcriptome of PEG-fused PNAs and to identify possible links between alterations of the extracellular matrix and suppression of the allorejection response. The results establish an initial molecular basis to understand mechanisms underlying PEG-mediated immunosuppression.

20 March 2021 in Diseases
Verified
Journal Article
Open access
PDF file
CSChristian Schmidt
Christian Schmidt
LCLaura Christian
Laura Christian
TSTyler Aaron Smith
Tyler Aaron Smith
JTJosephine Tidwell
Josephine Tidwell
DKDongkyoon Kim
Dongkyoon Kim
HTHaley Tucker
Haley Tucker
Several diseases originate via dysregulation of the actin cytoskeleton. The ARID3A/Bright transcription factor has also been implicated in malignancies, primarily those derived from hematopoietic lineages. Previously, we demonstrated that ARID3A shuttles between the nucleus and the plasma membrane, where it localizes within lipid rafts. There it interacts with components of the B-cell receptor (BCR) to reduce its ability to transmit downstream signaling. We demonstrate here that a direct component of ARID3A-regulated BCR signal strength is cortical actin. ARID3A interacts with actin exclusively within lipid rafts via the actin-binding protein EZRIN, which confines unstimulated BCRs within lipid rafts. BCR ligation discharges the ARID3A–EZRIN complex from lipid rafts, allowing the BCR to initiate downstream signaling events. The ARID3A–EZRIN interaction occurs almost exclusively within unpolymerized G-actin, where EZRIN interacts with the multifunctional ARID3A REKLES domain. These observations provide a mechanism by which a transcription factor directly regulates BCR signaling via linkage to the actin cytoskeleton with consequences for B-cell-related neoplasia.